Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Expert Opin Pharmacother ; 24(9): 1067-1073, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37128968

RESUMO

INTRODUCTION: Endometriosis is a benign chronic inflammatory disease responsible for debilitating pain and decreased quality of life. The traditional treatment is based on estroprogestins, progestins, GnRH analogs, and surgery. Recently, aromatase inhibitors (AIs) demonstrated good efficacy in controlling symptoms and size of endometriotic implants, mostly because they suppress extraovarian estrogen synthesis, which can enhance the hypoestrogenic state ameliorating symptoms of endometriosis. AREAS COVERED: Phase I, II, III and IV trials, on the use of AIs used for the treatment of endometriosis, have been retrieved. The pharmacokinetics and pharmacodynamics of third-generation non-steroidal AIs have also been investigated. A MEDLINE search has been performed using the following MeSH keywords: 'endometriosis,' aromatase inhibitors,' 'therapy,' and 'treatment'. The timeframe was from 2010 up to November 2022 including reviews, systematic reviews, reports, case series, and retrospective or prospective trials. EXPERT OPINION: AIs have shown good clinical efficacy in combination with hormonal therapy in disease control, and they represent a promising second-line therapy in selected patients, yet more research is needed on alternative drug delivery systems and better control of adverse effects. In postmenopausal women in which surgery is contraindicated, AIs represent an excellent treatment option. Their application in routine clinical practice remains limited by adverse effects.


Assuntos
Inibidores da Aromatase , Endometriose , Humanos , Feminino , Inibidores da Aromatase/efeitos adversos , Endometriose/tratamento farmacológico , Qualidade de Vida , Estudos Prospectivos , Estudos Retrospectivos
2.
Doc Ophthalmol ; 107(2): 111-4, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14661900

RESUMO

The authors describe their findings on 12 subjects who were treated with 50 mg of sildenafil (Viagra) and underwent ERG measurements prior to and 1 hour after ingestion. The Naka-Rushton equation was used to describe the b-wave luminance-response function of the scotopic ERG. Statistically significant differences were noted in the Vmax and K values. Sildenafil ingestion resulted in an increase in Vmax (higher rod response to light stimuli) and a decrease in K (higher sensitivity).


Assuntos
Disfunção Erétil/tratamento farmacológico , Disfunção Erétil/fisiopatologia , Inibidores de Fosfodiesterase/efeitos adversos , Piperazinas/efeitos adversos , Retina/efeitos dos fármacos , Retina/fisiopatologia , Eletrorretinografia , Humanos , Masculino , Pessoa de Meia-Idade , Purinas , Citrato de Sildenafila , Sulfonas , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA